المؤلفون: Wei Li, Wei Wang, Minlan Zhang, Qi Chen, Fengyi Li, Shaojun Li

المصدر: BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-8 (2024)

مصطلحات موضوعية: Glucocorticoid-induced osteoporosis, Sclerostin, Marrow adiposity, Magnetic resonance spectroscopy, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1472-6823Test

الوصول الحر: https://doaj.org/article/f4094d0da0af4aee91860bf2be7312a9Test

المؤلفون: Nonoko Ishihara, Shuji Yamashita, Shizuno Seiki, Keito Tsutsui, Hiroko Kato-Hayashi, Shuji Sakurai, Kyoko Niwa, Takuyoshi Kawai, Junko Kai, Akio Suzuki, Hideki Hayashi

المصدر: Pharmacy, Vol 12, Iss 3, p 80 (2024)

مصطلحات موضوعية: glucocorticoid-induced osteoporosis, evidence–practice gap, GIOP guidelines, tracing reports, pharmacist, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2226-4787/12/3/80Test; https://doaj.org/toc/2226-4787Test

الوصول الحر: https://doaj.org/article/dee0daf3725e42cb9aa7ec0f3826fdd2Test

المؤلفون: N. V. Toroptsova, E. L. Nasonov, Н. В. Торопцова, Е. Л. Насонов

المصدر: Rheumatology Science and Practice; Vol 62, No 2 (2024); 145-153 ; Научно-практическая ревматология; Vol 62, No 2 (2024); 145-153 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: клинические рекомендации, glucocorticoid-induced osteoporosis, fracture risk, osteoporosis treatment, guideline, глюкокортикоидный остеопороз, риск переломов, лечение остеопороза

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/3543/2360Test; Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):885-906. doi:10.1016/j.berh.2007.06.002; Баранова ИА, Ершова ОБ, Анаев ЭХ, Анохина ТН, Аношенкова ОН, Батын СЗ, и др. Оценка частоты и факторов риска низкоэнергетических переломов скелета по данным опроса больных хроническими воспалительными заболеваниями. Результаты многоцентрового исследования российской ассоциации по остеопорозу ГЛЮКОСТ. Остеопороз и остеопатии. 2014;17(3):9-14. doi:10.14341/osteo201439-14; Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383- 1389. doi:10.1093/rheumatology/39.12.1383; De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208-214. doi:10.1002/art.22294; Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int. 2011; 22:809-816. doi:10.1007/s00198-010-1524-7; Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi:10.1002/acr.25240; Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726-735. doi:10.1016/j.jclinepi.2013.02.003; Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD; Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58. doi:10.1210/jc.2010-2704; Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis [review]. Cochrane Database Syst Rev. 2016;10:CD001347. doi:10.1002/14651858.CD001347.pub2; Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039. doi:10.1056/NEJMoa071408; Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724-738. doi:10.20945/2359-3997000000564; Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253- 1263. doi:10.1016/S0140-6736(09)60250-6; Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoidinduced osteoporosis: A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445-454. doi:10.1016/S2213-8587(18)30075-5; Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. doi:10.1002/art.24879; Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68-73. doi:10.1002/(SICI)1096-9926(199908)60:23.0.CO;2-H; Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al.; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi:10.1038/sj.ki.5000414; Hiramatsu R, Ubara Y, Sawa N, Sakai A. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant. 2021;36:1900-1907. doi:10.1093/ndt/gfaa359; Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al.; EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852-860. doi:10.1210/jc.2007-0711; Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013;28(6):1328-1336. doi:10.1002/jbmr.1853; Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751. doi:10.1359/JBMR.040117; Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-1155. doi:10.1016/S0140-6736(15)61120-5; Cosman F. Anabolic and antiresorptive therapy for osteoporosis: Combination and sequential approaches. Curr Osteoporos Rep. 2014;12:385-395. doi:10.1007/s11914-014-0237-9; Cosman F, Huang S, McDermott M, Cummings SR. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res. 2022;37(11):2112-2120. doi:10.1002/jbmr.4705; Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221; Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2020;105(3):e255-e264. doi:10.1210/clinem/dgz095; Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: A retrospective study. Osteoporos Int. 2023;34(3):573-584. doi:10.1007/s00198-022-06648-9; Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide follow-up study (DATA-Follow-up). Bone. 2017;98:54-58. doi:10.1016/j.bone.2017.03.006; Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, et al. Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int. 2022;33(6):1243-1256. doi:10.1007/s00198-021-06174-0; Solling AS, Harslof T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: A 2-year randomized study. J Bone Miner Res. 2021;36:1245-1254. doi:10.1002/jbmr.4305.; Napoli N, Langdahl BL, Ljunggren Ö, Lespessailles E, Kapetanos G, Kocjan T, et al. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo® Observational Study (ExFOS). Calcif Tissue Int. 2018;103(4):359-371. doi:10.1007/s00223-018-0437-x; Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: A network meta-analysis. Osteoporos Int. 2016;27(6):1989-1998. doi:10.1007/s00198-015-3476-4; Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl 2):407-413. doi:10.1007/s00198-010-1253-y; de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589-602. doi:10.1007/s00198-004-1614-5; Белая ЖЕ, Белова КЮ, Бирюкова ЕВ, Дедов ИИ, Дзеранова ЛК, Драпкина ОМ, и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4-47. doi:10.14341/osteo12930; Лесняк ОМ (ред.). Остеопороз; 2-е издание, переработанное и дополненное. М.:ГЭОТАР-Медиа;2023.; https://rsp.mediar-press.net/rsp/article/view/3543Test

الإتاحة: https://doi.org/10.47360/1995-4484-2024-145-153Test
https://doi.org/10.1016/j.berh.2007.06.002Test
https://doi.org/10.14341/osteo201439-14Test
https://doi.org/10.1093/rheumatology/39.12.1383Test
https://doi.org/10.1002/art.22294Test
https://doi.org/10.1007/s00198-010-1524-7Test
https://doi.org/10.1002/acr.25240Test
https://doi.org/10.1016/j.jclinepi.2013.02.003Test
https://doi.org/10.1136/bmj.39489.470347.ADTest
https://doi.org/10.1210/jc.2010-2704Test

المؤلفون: Zeng Chenying, Wang Shan, Gu Huimin, Chen Fenglei, Wang Ziming, Li Jinteng, Xie Zhongyu, Feng Pei, Shen Huiyong, Wu Yanfeng

المصدر: Acta Biochimica et Biophysica Sinica, Vol 55, Pp 1275-1287 (2023)

مصطلحات موضوعية: galangin, glucocorticoid-induced osteoporosis, dexamethasone, BMSC, autophagy, Biochemistry, QD415-436, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1672-9145Test

الوصول الحر: https://doaj.org/article/86a3670ba62e47519ede5c4467435a7bTest

المؤلفون: Mengxing Yin, Dezhi Zhou, Fu Jia, Xiaosan Su, Xiufang Li, Ruifen Sun, Junmin Li

المصدر: Journal of Orthopaedic Surgery and Research, Vol 18, Iss 1, Pp 1-14 (2023)

مصطلحات موضوعية: Bone metabolism, Glucocorticoid-induced osteoporosis, Metabolomics, Taurine and hypotaurine metabolism, Yi-Guan-Jian decoction, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1749-799XTest

الوصول الحر: https://doaj.org/article/d7ebfb6c9956473dbe05f221497ce39fTest

المؤلفون: O. O. Lisakovska, I. O. Shymanskyi, V. M. Vasylevska, E. P. Pasichna, M. M. Veliky, S. V. Komisarenko

المصدر: The Ukrainian Biochemical Journal, Vol 95, Iss 2, Pp 33-47 (2023)

مصطلحات موضوعية: bone remode­ling, glucocorticoid-induced osteoporosis, methylenebisphosphonic acid, rank/rankl/opg axis, vitamin d3, Biochemistry, QD415-436, Medicine, Biology (General), QH301-705.5

وصف الملف: electronic resource

العلاقة: http://ukrbiochemjournal.org/wp-content/uploads/2023/06/Lisakovska_95_2.pdfTest; https://doaj.org/toc/2409-4943Test; https://doaj.org/toc/2413-5003Test

الوصول الحر: https://doaj.org/article/5d81b29e848b471faca866ad9e0c8f78Test

المؤلفون: Peiyu Wu, Feng Jiao, He Huang, Donghua Liu, Wang Tang, Jie Liang, Wen Chen

المصدر: Pharmaceutical Biology, Vol 60, Iss 1, Pp 1303-1316 (2022)

مصطلحات موضوعية: Glucocorticoid-induced osteoporosis, microarray analysis, microRNA-101-3p, prostaglandin-endoperoxide synthase 2, RANKL, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1388-0209Test; https://doaj.org/toc/1744-5116Test

الوصول الحر: https://doaj.org/article/6940350c48eb4dea9469a3df5bebb813Test

المؤلفون: Rong X, Kou Y, Zhang Y, Yang P, Tang R, Liu H, Li M

المصدر: Drug Design, Development and Therapy, Vol Volume 16, Pp 3929-3946 (2022)

مصطلحات موضوعية: glucocorticoid-induced osteoporosis, eldecalcitol, osteoblasts, notch signaling, wnt/gsk-3β/β-catenin signaling., Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/ed-71-preventsTest-glucocorticoid-induced-osteoporosis-by-regulating-osteo-peer-reviewed-fulltext-article-DDDT; https://doaj.org/toc/1177-8881Test

الوصول الحر: https://doaj.org/article/4f21008dee8c403192d195b18dbdabfeTest

المؤلفون: Satoshi Yamasaki, Kenjiro Kamezaki, Yoshikiyo Ito, Takahiko Horiuchi

المصدر: Hematology Reports, Vol 14, Iss 3, Pp 276-285 (2022)

مصطلحات موضوعية: immune thrombocytopenia, glucocorticoid-induced osteoporosis, elderly patients, FRAX®, Garvan tool, bisphosphonate, Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2038-8330/14/3/39Test; https://doaj.org/toc/2038-8330Test

الوصول الحر: https://doaj.org/article/ed10d25cc4c14277a6cc505143ac271bTest

المصدر: Zhongguo quanke yixue, Vol 25, Iss 06, Pp 756-759 (2022)

مصطلحات موضوعية: osteoporosis, glucocorticoid-induced osteoporosis, denosumab, sclerostin, dickkopf-1, monocolonal antibody, Medicine

وصف الملف: electronic resource

العلاقة: https://www.chinagp.net/fileup/1007-9572/PDF/1643096232815-1974372297.pdfTest; https://doaj.org/toc/1007-9572Test

الوصول الحر: https://doaj.org/article/c07d567eb6da4a5b8e56433609b1a6a3Test